8-K: FOXO Technologies Regains NYSE American Compliance After Debt-to-Equity Conversions

FOXO Technologies has announced that recent transactions, including debt-to-equity conversions, have resulted in stockholders' equity exceeding $4 million, allowing the company to regain compliance with NYSE American listing requirements.

Summary

• FOXO Technologies has successfully regained compliance with NYSE American listing requirements for stockholders' equity.
• Recent transactions have increased the company's stockholders' equity to over $4 million.
• The company had a stockholders' deficit of approximately $17.5 million as of September 30, 2024.
• FOXO secured agreements to convert debt into equity, including $21 million from Rennova Health into 21,000 shares of Series A Preferred Stock.
• An institutional investor provided an additional $1 million and converted $2.2 million of Senior Notes into 2,464 shares of Series A Preferred Stock.
• Liabilities to KR8 AI, Inc. were settled, and a license agreement was terminated in exchange for 3,000 shares of Series D Preferred Stock.
• Approximately $1 million of other liabilities and notes were converted into 2 million shares of Class A Common Stock since October 1, 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the company regaining compliance with NYSE American listing requirements and successfully converting debt to equity. However, the company still faces risks and challenges, which temper the overall sentiment.

Positives

• The company has successfully regained compliance with NYSE American listing requirements.
• The risk of delisting due to a stockholders' equity deficiency has been eliminated.
• The company has secured significant debt-to-equity conversions, improving its balance sheet.
• Management is committed to continued growth and improvements for the benefit of shareholders.

Negatives

• The company previously had a significant stockholders' deficit of $17.5 million as of September 30, 2024.
• The company was at risk of being delisted from the NYSE American due to the stockholders' equity deficiency.
• The company has a history of losses and may not achieve or maintain profitability in the future.

Risks

• If the company falls out of compliance with stockholders' equity requirements in the future, it will be subject to immediate reevaluation by NYSE American.
• The company faces risks related to the competitive and highly regulated industries in which it operates.
• There are risks associated with the company's ability to obtain financing and implement its business plans.
• The company may not be able to establish or maintain relationships required to advance its goals.
• There are risks related to the enforceability of the company's intellectual property and potential infringement on the intellectual property rights of others.
• The company is subject to the risk of downturns and a changing regulatory landscape in the biotechnology industry.

Future Outlook

The company is committed to continued growth and improvements for the benefit of its shareholders in the coming years. However, the company is subject to reevaluation by NYSE American if it falls out of compliance with stockholders' equity requirements in the future.

Management Comments

• We are delighted we can inform our shareholders that stockholders equity is now greater than $4 million, said Seamus Lagan, the Company's Chief Executive Officer.
• We believe this eliminates the risk of delisting from NYSE American for a stockholders equity deficiency that has hung over the Company for the past 18 months.
• We are committed to continued growth and improvements for the benefit of our shareholders in the coming years, continued Mr. Lagan.

Industry Context

This announcement is significant for FOXO as it addresses a critical compliance issue with the NYSE American exchange. The company's ability to secure debt-to-equity conversions is a positive sign, especially in the competitive biotechnology and healthcare sectors where financial stability is crucial for investor confidence and continued operations.

Comparison to Industry Standards

• Many small-cap biotech companies face challenges in maintaining listing compliance, particularly regarding stockholders' equity.
• The successful debt-to-equity conversion by FOXO is similar to strategies employed by other companies in the sector to improve their balance sheets and avoid delisting.
• Companies like Rennova Health, which participated in the debt conversion, often engage in such transactions to manage their own financial positions and strategic investments.
• The use of preferred stock as a means of raising capital and converting debt is a common practice in the industry, especially for companies with limited access to traditional financing.

Related Party Transactions

• The company engaged in transactions with Rennova Health, Inc., a related party, to convert $21 million of debt into equity.

Stakeholder Impact

• Shareholders will benefit from the company regaining compliance with NYSE American listing requirements.
• Creditors and debt holders have converted their debt into equity, potentially improving their long-term prospects.
• The company's employees may experience increased job security due to the improved financial position.

Next Steps

• The company will continue to focus on growth and improvements for the benefit of its shareholders.
• The company will need to maintain compliance with NYSE American listing requirements to avoid future reevaluation.

Key Dates

Keywords

stockholders equity, NYSE American, debt-to-equity conversion, listing requirements, preferred stock, delisting, financial compliance, Rennova Health, KR8 AI, Series A Preferred Stock, Series D Preferred Stock